{"pub_date": "2016-12-19T20:08:58+0000", "subsection_name": null, "lead_paragraph": "Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?", "print_page": "1", "document_type": "article", "byline": {"contributor": "", "person": [{"rank": 1, "organization": "", "lastname": "RICHTEL", "firstname": "Matt", "role": "reported"}, {"rank": 2, "organization": "", "lastname": "POLLACK", "firstname": "Andrew", "role": "reported"}], "original": "By MATT RICHTEL and ANDREW POLLACK"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 400, "url": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/12/19/science/19IMMUNO-COMBO/19IMMUNO-COMBO-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Health", "headline": {"content_kicker": "Public Labs, Corporate Gains", "print_headline": "Taxpayers Finance Cancer Drug, but the Profits Will Be Private", "main": "Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits", "kicker": "Public Labs, Corporate Gains"}, "source": "The New York Times", "blog": [], "word_count": "3187", "web_url": "http://www.nytimes.com/2016/12/19/health/harnessing-the-us-taxpayer-to-fight-cancer-and-make-profits.html", "slideshow_credits": null, "news_desk": "National", "type_of_material": "News", "snippet": "Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?...", "_id": "58583e6395d0e03926076d65", "abstract": "Partnership between federal government and drug company Kite Pharma to develop cancer immunotherapy treatment raises concerns that taxpayers are getting raw deal; critics charge that taxpayers will end up paying twice for same drug--once to support its development and second time to purchase it--while company reaps financial benefit, whereas proponents say such partnerships are best way to deliver life-saving drugs to public (Series: Cell Wars).", "keywords": [{"rank": "1", "name": "subject", "value": "Cancer", "is_major": "Y"}, {"rank": "2", "name": "subject", "value": "Immune System", "is_major": "Y"}, {"rank": "3", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y"}, {"rank": "4", "name": "organizations", "value": "Kite Pharma Inc.", "is_major": "Y"}, {"rank": "5", "name": "organizations", "value": "National Cancer Institute", "is_major": "N"}, {"rank": "6", "name": "persons", "value": "Belldegrun, Arie S", "is_major": "N"}, {"rank": "7", "name": "subject", "value": "Inventions and Patents", "is_major": "N"}, {"rank": "8", "name": "persons", "value": "Rosenberg, Steven A", "is_major": "N"}, {"rank": "9", "name": "subject", "value": "Series", "is_major": "Y"}]}